Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Malignant Melanoma

Free Subscription Articles published in Melanoma Res Retrieve available abstracts of 274 articles: HTML format

Single Articles

April 2024
1. WU LW, Tao JJ, McDonnell D, Izar B, et al
   Pseudoprogression in a patient with metastatic melanoma treated with PD-1 and LAG-3 inhibition.
   Melanoma Res. 2024 Apr 18. doi: 10.1097/CMR.0000000000000974.
   PubMed     Abstract available
   
   
   
2. SUWAJANAKORN D, Lane AM, Go AK, Hartley CD, et al
   Impact of gene expression profiling on diagnosis and survival after metastasis in patients with uveal melanoma.
   Melanoma Res. 2024 Apr 5. doi: 10.1097/CMR.0000000000000971.
   PubMed     Abstract available
   
   
   
3. HENNEMANN A, Puzenat E, Decreuse M, Vuillier F, et al
   Intracranial hemorrhage caused by dabrafenib and trametinib therapy for metastatic melanoma.
   Melanoma Res. 2024 Apr 5. doi: 10.1097/CMR.0000000000000820.
   PubMed     Abstract available
   
   
   
4. MAIONE V, Perantoni M, Bettolini L, Bighetti S, et al
   Influence of regression, its extent and tumor-infiltrating lymphocytes on sentinel node status, relapse, and survival in a 10-year retrospective study of melanoma patients.
   Melanoma Res. 2024 Apr 2. doi: 10.1097/CMR.0000000000000970.
   PubMed     Abstract available
   
   
   March 2024
5. KODALI N, Bhattaru A, Blanchard I, Sharma Y, et al
   Assessing melanoma prognosis: the interplay between patient profiles, survival, and BRAF, NRAS, KIT, and TWT mutations in a retrospective multi-study analysis.
   Melanoma Res. 2024 Mar 29. doi: 10.1097/CMR.0000000000000968.
   PubMed     Abstract available
   
   
   
6. FABRE M, Lamoureux A, Meunier L, Samaran Q, et al
   Efficiency and tolerance of second-line triple BRAF inhibitor/MEK inhibitor/anti-PD1 combined therapy in BRAF mutated melanoma patients with central nervous system metastases occurring during first-line combined targeted therapy: a real-life survey.
   Melanoma Res. 2024 Mar 28. doi: 10.1097/CMR.0000000000000963.
   PubMed     Abstract available
   
   
   
7. NEKKANTI SS, Nusrath S, Jarang R, Rayani BK, et al
   Feasibility and efficacy of indocyanine green in monitoring systemic drug leakage during isolated limb perfusion for recurrent melanoma of extremity.
   Melanoma Res. 2024 Mar 15. doi: 10.1097/CMR.0000000000000967.
   PubMed     Abstract available
   
   
   
8. LEROY M, Desmedt E, Deramoudt L, Vasseur M, et al
   Retrospective comparison of a weight-based dose every 2 weeks with a fixed dose every month: a real-life analysis of nivolumab in the treatment of advanced melanoma.
   Melanoma Res. 2024 Mar 15. doi: 10.1097/CMR.0000000000000965.
   PubMed     Abstract available
   
   
   
9. WANG P, Liu T, Zhang Q, Luo P, et al
   Genetic causal relationship between gut microbiota and cutaneous melanoma: a two-sample Mendelian randomization study.
   Melanoma Res. 2024 Mar 11. doi: 10.1097/CMR.0000000000000960.
   PubMed     Abstract available
   
   
   
10. NG CA, Luckett T, Mulhern B, Kee D, et al
    What matters most to people with metastatic uveal melanoma? A qualitative study to inform future measurement of health-related quality of life.
    Melanoma Res. 2024 Mar 5. doi: 10.1097/CMR.0000000000000961.
    PubMed     Abstract available
    
    
    February 2024
11. DE PINTO G, Mignozzi S, La Vecchia C, Levi F, et al
    Global trends in cutaneous malignant melanoma incidence and mortality.
    Melanoma Res. 2024 Feb 21. doi: 10.1097/CMR.0000000000000959.
    PubMed     Abstract available
    
    
    
12. TEIXEIRA RJ, de Souza VG, Sorroche BP, Paes VG, et al
    Immunohistochemistry assessment of tissue neutrophil-to-lymphocyte ratio (tNLR) predicts outcomes in melanoma patients treated with anti-programmed cell death 1 therapy.
    Melanoma Res. 2024 Feb 16. doi: 10.1097/CMR.0000000000000958.
    PubMed     Abstract available
    
    
    
13. ZHANG W, Wang S
    Machine learning developed an intratumor heterogeneity signature for predicting prognosis and immunotherapy benefits in skin cutaneous melanoma.
    Melanoma Res. 2024 Feb 16. doi: 10.1097/CMR.0000000000000957.
    PubMed     Abstract available
    
    
    
14. DE SMEDT J, Aura C, Van Kelst S, Janssen L, et al
    Clinical and genetic determinants of vitamin D receptor expression in cutaneous melanoma patients.
    Melanoma Res. 2024 Feb 13. doi: 10.1097/CMR.0000000000000929.
    PubMed     Abstract available
    
    
    
15. DELZENNE G, Boileau M, Jamme P, Farchi O, et al
    Relevance of detection of RAF fusion transcripts in pan-negative melanoma in routine practice.
    Melanoma Res. 2024 Feb 7. doi: 10.1097/CMR.0000000000000955.
    PubMed     Abstract available
    
    
    
16. ERCAN A, Yalcin CE
    Neonatal cutaneous melanoma with cutaneous metastasis: a case report and review of literature.
    Melanoma Res. 2024 Feb 7. doi: 10.1097/CMR.0000000000000956.
    PubMed     Abstract available
    
    
    
17. DIAZ MJ, Quach J, Song J, Milanovic S, et al
    Hypoxic transcriptomes predict survival and tumor-infiltrating immune cell composition in cutaneous melanoma.
    Melanoma Res. 2024 Feb 7. doi: 10.1097/CMR.0000000000000938.
    PubMed     Abstract available
    
    
    
18. GEIGER CE, Mrabet-Dahbi S, Berger I
    The BRAF and NRAS status among distinct metastases of malignant melanoma differ significantly independent of tissue origin and temporal occurrence. Possible effect on clinical relevance?
    Melanoma Res. 2024;34:85-87.
    PubMed    
    
    
    
19. ROSTER K, Thang C, Islam S, Lipner SR, et al
    Underreporting of acral lentiginous melanoma in studies informing American Joint Committee on Cancer Staging System Guidelines: a review of 150 cited studies.
    Melanoma Res. 2024;34:84-88.
    PubMed    
    
    
    
20. DUARTE R, Trigo F, Luz I, Santos P, et al
    Small-vessel vasculitis leading to severe acute kidney injury after ipilimumab: a case report.
    Melanoma Res. 2024;34:76-79.
    PubMed     Abstract available
    
    
    January 2024
21. DAVIDSON TM, Hieken TJ, Glasgow AE, Habermann EB, et al
    Pregnancy-associated melanoma: characteristics and outcomes from 2002 to 2020.
    Melanoma Res. 2024 Jan 23. doi: 10.1097/CMR.0000000000000953.
    PubMed     Abstract available
    
    
    
22. KOSTAKI M, Plaka M, Befon A, Dessinioti C, et al
    Simultaneous melanomas in the setting of multiple primary melanomas.
    Melanoma Res. 2024 Jan 15. doi: 10.1097/CMR.0000000000000954.
    PubMed     Abstract available
    
    
    
23. PARISA S, Amirhossein I, Hamed YS, Javad F, et al
    The effect of microRNA-9 overexpression on inhibition of melanoma cancer stem cells tumorigenicity.
    Melanoma Res. 2024 Jan 15. doi: 10.1097/CMR.0000000000000931.
    PubMed     Abstract available
    
    
    
24. KO B, Tao K, Brennan L, Rakhade S, et al
    Evaluating the efficacy of combination and single-agent immunotherapies in real-world patterns of disease progression and survival of metastatic melanoma patients.
    Melanoma Res. 2024 Jan 5. doi: 10.1097/CMR.0000000000000945.
    PubMed     Abstract available
    
    
    December 2023
25. LOUVEAU B, Reger De Moura C, Jouenne F, Sadoux A, et al
    Combined PDE4+MEK inhibition shows antiproliferative effects in NRASQ61 mutated melanoma preclinical models.
    Melanoma Res. 2023 Dec 22. doi: 10.1097/CMR.0000000000000950.
    PubMed     Abstract available
    
    
    
26. YEE J, Rosendahl C, Aoude LG
    The role of artificial intelligence and convolutional neural networks in the management of melanoma: a clinical, pathological, and radiological perspective.
    Melanoma Res. 2023 Dec 22. doi: 10.1097/CMR.0000000000000951.
    PubMed     Abstract available
    
    
    
27. ROSHARDT PRIETO NM, Turko P, Zellweger C, Nguyen-Kim TDL, et al
    Patterns of radiological response to tebentafusp in patients with metastatic uveal melanoma.
    Melanoma Res. 2023 Dec 19. doi: 10.1097/CMR.0000000000000952.
    PubMed     Abstract available
    
    
    
28. YAN J, Wang H, Lu X, Li F, et al
    Development and validation of a nomogram for elderly patients with ulcerative melanoma.
    Melanoma Res. 2023 Dec 13. doi: 10.1097/CMR.0000000000000940.
    PubMed     Abstract available
    
    
    
29. BAFALOUKOS D, Kouzis P, Gouveris P, Boukovinas I, et al
    Real-world management practices and characteristics of patients with advanced melanoma initiated on immuno-oncology or targeted therapy in the first-line setting during the period 2015-2018 in Greece. The 'SUMMER' study: a retrospective multicenter ch
    Melanoma Res. 2023 Dec 13. doi: 10.1097/CMR.0000000000000949.
    PubMed     Abstract available
    
    
    
30. RICHTIG E, Nguyen VA, Koelblinger P, Wolf I, et al
    Dabrafenib plus trametinib in unselected advanced BRAF V600-mut melanoma: a non-interventional, multicenter, prospective trial.
    Melanoma Res. 2023 Dec 13. doi: 10.1097/CMR.0000000000000948.
    PubMed     Abstract available
    
    
    
31. SWITZER B, Puzanov I, Gandhi S, Repasky EA, et al
    Targeting beta-adrenergic receptor pathways in melanoma: how stress modulates oncogenic immunity.
    Melanoma Res. 2023 Dec 4. doi: 10.1097/CMR.0000000000000943.
    PubMed     Abstract available
    
    
    
32. PARISI R, Shah H, Everdell E, Feustel P, et al
    First-time office visit for suspicious skin lesion evaluation as a predictor of high-risk melanoma.
    Melanoma Res. 2023;33:555-556.
    PubMed    
    
    
    
33. CARMONA-ROCHA E, Sullivan I, Yelamos O
    Vitiligo-like hypopigmentation induced by dabrafenib-trametinib: a potential marker for clinical response.
    Melanoma Res. 2023;33:553-555.
    PubMed    
    
    
    
34. TAN SX, Chong S, Rowe C, Claeson M, et al
    pSTAT5 is associated with improved survival in patients with thick or ulcerated primary cutaneous melanoma.
    Melanoma Res. 2023;33:506-513.
    PubMed     Abstract available
    
    
    
35. MEYER SN, Simmons E, Studer AC, Rauen KA, et al
    Melanocytic neoplasms in neurofibromatosis type 1: a systematic review.
    Melanoma Res. 2023;33:437-446.
    PubMed     Abstract available
    
    
    
36. VIGNESWARAN G, Malalasekera W, Smith V, Gibson T, et al
    Quality of life after melphalan percutaneous hepatic perfusion for patients with metastatic Uveal Melanoma.
    Melanoma Res. 2023 Dec 1. doi: 10.1097/CMR.0000000000000947.
    PubMed     Abstract available
    
    
    November 2023
37. STAHLIE EHA, Zijlker LP, Wouters MWJM, Schrage YM, et al
    Real-world relapse-free survival data on adjuvant anti-PD-1 therapy for patients with newly diagnosed and recurrent stage III melanoma.
    Melanoma Res. 2023 Nov 28. doi: 10.1097/CMR.0000000000000946.
    PubMed     Abstract available
    
    
    
38. MEZOLAKI NE, Baltas E, Ocsai HL, Varga A, et al
    Tumour regression predicts better response to interferon therapy in melanoma patients: a retrospective single centre study.
    Melanoma Res. 2023 Nov 13. doi: 10.1097/CMR.0000000000000935.
    PubMed     Abstract available
    
    
    
39. KAHLER KC, Debus D, Schley G, Goppner D, et al
    Effectiveness, safety and utilization of cobimetinib and vemurafenib in patients with BRAF V600 mutant melanoma with and without cerebral metastasis under real-world conditions in Germany: the non-interventional study coveNIS.
    Melanoma Res. 2023 Nov 13. doi: 10.1097/CMR.0000000000000908.
    PubMed     Abstract available
    
    
    
40. PAOLINO G, Carugno A, Rongioletti F, Ponzoni M, et al
    Bone marrow metastases: a systematic review of a neglected involvement in malignant melanoma.
    Melanoma Res. 2023 Nov 8. doi: 10.1097/CMR.0000000000000942.
    PubMed     Abstract available
    
    
    
41. CHEN W, Yang C, Chen B, Xi M, et al
    Management of metastatic bone disease of melanoma.
    Melanoma Res. 2023 Nov 8. doi: 10.1097/CMR.0000000000000937.
    PubMed     Abstract available
    
    
    
42. TAIBO A, Paradela S, Suanzes-Hernandez J, Balboa-Barreiro V, et al
    Prognosis of CDKN2A germline mutation in patients with familial melanoma: a systematic review and meta-analysis.
    Melanoma Res. 2023 Nov 2. doi: 10.1097/CMR.0000000000000920.
    PubMed     Abstract available
    
    
    
43. GAMBICHLER T, Iordanou M, Becker JC, Susok L, et al
    Intratumoural and systemic inflammation as predictors for treatment response in BRAF-mutated melanoma patients under targeted therapies.
    Melanoma Res. 2023 Nov 2. doi: 10.1097/CMR.0000000000000934.
    PubMed     Abstract available
    
    
    
44. KIM HE, Kim J, Park HK, Lee JB, et al
    Correlations between inflammatory cytokine levels and degree of pigmentation in acral melanomas.
    Melanoma Res. 2023 Nov 2. doi: 10.1097/CMR.0000000000000939.
    PubMed     Abstract available
    
    
    
45. BENESCH MGK, Skitzki JJ
    Impact of anesthesia choice in cutaneous melanoma surgery.
    Melanoma Res. 2023 Nov 2. doi: 10.1097/CMR.0000000000000936.
    PubMed     Abstract available
    
    
    
46. KOHL LM, Sumpter TL
    Melanomas and mast cells: an ambiguous relationship.
    Melanoma Res. 2023 Nov 2. doi: 10.1097/CMR.0000000000000932.
    PubMed     Abstract available
    
    
    October 2023
47. CAO Y, Afzal MZ, Gutmann EJ, Shirai K, et al
    Rare immune-related adverse events in a patient with metastatic melanoma: a case report highlighting sarcoidosis-like reactions triggered by immune-checkpoint inhibitors.
    Melanoma Res. 2023 Oct 13. doi: 10.1097/CMR.0000000000000925.
    PubMed     Abstract available
    
    
    
48. SADA I, Harada Y, Hiyama T, Mizukami M, et al
    Uveitis associated with immune checkpoint inhibitors or BRAF/MEK inhibitors in patients with malignant melanoma.
    Melanoma Res. 2023 Oct 2. doi: 10.1097/CMR.0000000000000933.
    PubMed     Abstract available
    
    
    
49. RUBATTO M, Borriello S, Sciamarrelli N, Pala V, et al
    Exploring the role of epigenetic alterations and non-coding RNAs in melanoma pathogenesis and therapeutic strategies.
    Melanoma Res. 2023 Oct 2. doi: 10.1097/CMR.0000000000000926.
    PubMed     Abstract available
    
    
    
50. PHAM JP, Dwyer L, Phan K, Menzies AM, et al
    Efficacy of topical diphencyprone for melanoma in-transit metastases: a systematic review and meta-analysis.
    Melanoma Res. 2023;33:434-436.
    PubMed    
    
    
    
51. OZLUK AA, Karateke M, Sanli UA, Karaca B, et al
    Efficacy of local ablative therapies in patients with solid tumors treated with immune checkpoint inhibitors and oligoprogression: a single-center analysis.
    Melanoma Res. 2023;33:417-421.
    PubMed     Abstract available
    
    
    September 2023
52. BOUDREAU MW, Tonogai EJ, Schane CP, Xi MX, et al
    The combination of PAC-1 and entrectinib for the treatment of metastatic uveal melanoma.
    Melanoma Res. 2023 Sep 22. doi: 10.1097/CMR.0000000000000927.
    PubMed     Abstract available
    
    
    
53. SEGURA S, Podlipnik S, Boada A, Marti RM, et al
    Melanoma-specific survival in worse in the elderly: a multicentric cohort study.
    Melanoma Res. 2023 Sep 4. doi: 10.1097/CMR.0000000000000923.
    PubMed     Abstract available
    
    
    
54. LIN Z, Shen H, Liu X, Ma W, et al
    Recent advances of artificial intelligence in melanoma clinical practice.
    Melanoma Res. 2023 Sep 4. doi: 10.1097/CMR.0000000000000922.
    PubMed     Abstract available
    
    
    
55. UEMATSU M, Nakajima H, Hosono A, Kiyohara H, et al
    Safety of immune checkpoint inhibitors after proton beam therapy in head and neck mucosal melanoma: a case series.
    Melanoma Res. 2023 Sep 4. doi: 10.1097/CMR.0000000000000924.
    PubMed     Abstract available
    
    
    August 2023
56. LUO S, Xie C, Lin N, Lin D, et al
    Cost-effectiveness analysis of an orphan drug-tebentafusp in patients with metastatic uveal melanoma and a call for value-based pricing.
    Melanoma Res. 2023 Aug 25. doi: 10.1097/CMR.0000000000000919.
    PubMed     Abstract available
    
    
    
57. MATTEI J, Trindade EN, Chedid MF
    Mucosal melanoma: from molecular landscape to current treatment strategies.
    Melanoma Res. 2023 Aug 25. doi: 10.1097/CMR.0000000000000916.
    PubMed     Abstract available
    
    
    
58. MILEY DR, Andrews-Pfannkoch CM, Pulido JS, Erickson SA, et al
    Direct early growth response-1 knockdown decreases melanoma viability independent of mitogen-activated extracellular signal-related kinase inhibition.
    Melanoma Res. 2023 Aug 25. doi: 10.1097/CMR.0000000000000921.
    PubMed     Abstract available
    
    
    
59. LIU M, Lan Y, Zhang H, Zhang X, et al
    Telomere length is associated with increased risk of cutaneous melanoma: a Mendelian randomization study.
    Melanoma Res. 2023 Aug 25. doi: 10.1097/CMR.0000000000000917.
    PubMed     Abstract available
    
    
    
60. GJORUP CA, Pires da Silva I, Martin L, Stretch JR, et al
    Definitive treatment with PD-1 blockade and radiation therapy of unresected primary desmoplastic melanoma of the nose.
    Melanoma Res. 2023 Aug 3. doi: 10.1097/CMR.0000000000000905.
    PubMed     Abstract available
    
    
    
61. AUGUSTYN K, Joseph J, Patel AB, Razmandi A, et al
    Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice.
    Melanoma Res. 2023 Aug 3. doi: 10.1097/CMR.0000000000000891.
    PubMed     Abstract available
    
    
    July 2023
62. GLINKINA KA, Teunisse AFAS, Gelmi MC, de Vries J, et al
    Combined Mcl-1 and YAP1/TAZ inhibition for treatment of metastatic uveal melanoma.
    Melanoma Res. 2023 Jul 18. doi: 10.1097/CMR.0000000000000911.
    PubMed     Abstract available
    
    
    
63. FELICI C, Passarelli A, Cafforio P, Racanelli V, et al
    Lenalidomide arrests cell cycle and modulates PD1-dependent downstream mTOR intracellular signals in melanoma cells.
    Melanoma Res. 2023 Jul 12. doi: 10.1097/CMR.0000000000000913.
    PubMed     Abstract available
    
    
    
64. PELIZZARI G, Bertoli E, Buriolla S, Vitale MG, et al
    Estimating survival in patients with melanoma brain metastases: prognostic value of lactate dehydrogenase.
    Melanoma Res. 2023 Jul 3. doi: 10.1097/CMR.0000000000000907.
    PubMed     Abstract available
    
    
    June 2023
65. GIRONI LC, Esposto E, Zottarelli F, Giorgione R, et al
    Temporal correlation between the first melanoma and the first noncutaneous tumor in CKDN2A genotyped patients.
    Melanoma Res. 2023 Jun 21. doi: 10.1097/CMR.0000000000000906.
    PubMed     Abstract available
    
    
    
66. HE K, Hong DS, Ke D, Kebriaei P, et al
    Durable control of metastases in an HLA-A2+ patient with refractory melanoma after low-dose radiotherapy in combination with MAGE-A4 T cell therapy: a case report.
    Melanoma Res. 2023 Jun 16. doi: 10.1097/CMR.0000000000000869.
    PubMed     Abstract available
    
    
    
67. ASSEFA W, Muluye S, Assefa A, Alemu Y, et al
    A glimpse at locally advanced melanomas in the settings of poverty: pathologists viewpoint.
    Melanoma Res. 2023 Jun 13. doi: 10.1097/CMR.0000000000000909.
    PubMed     Abstract available
    
    
    
68. KISISTOK J, Christensen DS, Rasmussen MH, Duval L, et al
    Analysis of circulating tumor DNA during checkpoint inhibition in metastatic melanoma using a tumor-agnostic panel.
    Melanoma Res. 2023 Jun 12. doi: 10.1097/CMR.0000000000000903.
    PubMed     Abstract available
    
    
    
69. GARCIA-PEREZ O, Melgar-Vilaplana L, Sifaoui I, Garcia-Bello MA, et al
    Expression of angiogenic and lymphangiogenic genes in primary cutaneous melanoma: relationship with angiolymphatic invasion and disease-free survival.
    Melanoma Res. 2023 Jun 12. doi: 10.1097/CMR.0000000000000904.
    PubMed     Abstract available
    
    
    
70. AMARA SV, Grbic N, Melson G, Brem CE, et al
    Assessment of lipid and pigment content in suspicious melanocytic lesions to improve melanoma detection.
    Melanoma Res. 2023 Jun 5. doi: 10.1097/CMR.0000000000000902.
    PubMed     Abstract available
    
    
    
71. CHERSI F, Conforti C, Zalaudek I, Bazzacco G, et al
    Clinical and dermoscopical presentation of nivolumab-induced pemphigoid in a metastatic melanoma patient.
    Melanoma Res. 2023;33:262-263.
    PubMed    
    
    
    May 2023
72. AGNILA DRL, Huda TI, Eakins RA, Patel DN, et al
    Chemical features of melanoma tumor resident TRG CDR3s associated with better survival probabilities.
    Melanoma Res. 2023 May 23. doi: 10.1097/CMR.0000000000000899.
    PubMed     Abstract available
    
    
    
73. SHELLENBERGER RA, Gowda S, Kurn H, Albright J, et al
    Vitamin D insufficiency and serum levels related to the incidence and stage of cutaneous melanoma: a systematic review and meta-analysis.
    Melanoma Res. 2023 May 18. doi: 10.1097/CMR.0000000000000897.
    PubMed     Abstract available
    
    
    
74. PHAM JP, On L, Ardolino L, Hurwitz J, et al
    Efficacy of immune checkpoint inhibition in metastatic uveal melanoma: a systematic review and meta-analysis.
    Melanoma Res. 2023 May 18. doi: 10.1097/CMR.0000000000000900.
    PubMed     Abstract available
    
    
    
75. YOO H, Park S, Kim SW
    Nodular type predominance of head and neck cutaneous malignant melanoma in Asian populations leads to poor outcome and low survival.
    Melanoma Res. 2023 May 18. doi: 10.1097/CMR.0000000000000901.
    PubMed     Abstract available
    
    
    
76. MATTAVELLI I, Patuzzo R, Galeone C, Pelucchi C, et al
    Potential risk factors, clinicopathological features and determinants of survival for multiple primary melanoma patients compared to single primary melanoma: a large single-center Italian study.
    Melanoma Res. 2023 May 8. doi: 10.1097/CMR.0000000000000898.
    PubMed     Abstract available
    
    
    
77. OGATA D, Nishio S, Hatta N, Kaji T, et al
    Clinicopathological demographics of malignant melanomas of the vulva and vagina in Japan.
    Melanoma Res. 2023 May 8. doi: 10.1097/CMR.0000000000000894.
    PubMed     Abstract available
    
    
    April 2023
78. DIRVEN I, Vander Mijnsbrugge AS, Mignon S, Tijtgat J, et al
    Auto-immune hemolytic anemia and hemophagocytic lymphohistiocytosis as immune-related adverse event in patients with metastatic melanoma and concurrent chronic lymphocytic leukemia: a case series and literature review.
    Melanoma Res. 2023 Apr 28. doi: 10.1097/CMR.0000000000000895.
    PubMed     Abstract available
    
    
    
79. WONG CK, Dite GS, Spaeth E, Murphy NM, et al
    Melanoma risk prediction based on a polygenic risk score and clinical risk factors.
    Melanoma Res. 2023 Apr 24. doi: 10.1097/CMR.0000000000000896.
    PubMed     Abstract available
    
    
    
80. MOHAMMADI A, Najafi S, Amini M, Baradaran B, et al
    B7H6 silencing increases chemosensitivity to dacarbazine and suppresses cell survival and migration in cutaneous melanoma.
    Melanoma Res. 2023 Apr 12. doi: 10.1097/CMR.0000000000000890.
    PubMed     Abstract available
    
    
    
81. STATHAKI MI, Kapsoritakis N, Michelakis D, Anagnostopoulou E, et al
    The impact of sentinel lymph node mapping with hybrid single photon emission computed tomography/computed tomography in patients with melanoma. Comparison to planar radioisotopic lymphoscintigraphy.
    Melanoma Res. 2023 Apr 12. doi: 10.1097/CMR.0000000000000893.
    PubMed     Abstract available
    
    
    
82. BRUNSGAARD EK, Bowles TL, Asare EA, Grossmann K, et al
    Feasibility of personalized circulating tumor DNA detection in stage II and III melanoma.
    Melanoma Res. 2023 Apr 5. doi: 10.1097/CMR.0000000000000892.
    PubMed     Abstract available
    
    
    
83. CYBULSKA-STOPA B, Piejko K, Ostaszewski K, Dziura R, et al
    Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma treatment.
    Melanoma Res. 2023 Apr 3. doi: 10.1097/CMR.0000000000000885.
    PubMed     Abstract available
    
    
    
84. LE GOUBEY JB, Sassier M, Nakouri I, De Pontville M, et al
    Recurrent hemophagocytic lymphohistiocytosis in advanced melanoma treated with two different BRAF/MEK-inhibitor regimens.
    Melanoma Res. 2023;33:159-161.
    PubMed    
    
    
    
85. FORTMAN D, Avellan MGP, Hurd D, Schwartz M, et al
    Screening costs associated with donor selection for fecal microbiota transplantation for treatment of PD-1 refractory melanoma patients.
    Melanoma Res. 2023;33:136-148.
    PubMed     Abstract available
    
    
    
86. INGEN-HOUSZ-ORO S, Milpied B, Bensaid B, Elshot Y, et al
    Drug reactions with eosinophilia and systemic symptoms induced by immune checkpoint inhibitors: an international cohort of 13 cases.
    Melanoma Res. 2023;33:155-158.
    PubMed     Abstract available
    
    
    March 2023
87. MANZANO JL, Martin-Liberal J, Fernandez-Morales LA, Benitez G, et al
    Adjuvant dabrafenib and trametinib for patients with resected BRAF-mutated melanoma: DESCRIBE-AD real-world retrospective observational study.
    Melanoma Res. 2023 Mar 28. doi: 10.1097/CMR.0000000000000888.
    PubMed     Abstract available
    
    
    
88. VUILLAMY C, Arnault JP, Fumery M, Mortier L, et al
    Clostridium difficile infection and immune checkpoint inhibitor-induced colitis in melanoma: 18 cases and a review of the literature.
    Melanoma Res. 2023 Mar 27. doi: 10.1097/CMR.0000000000000878.
    PubMed     Abstract available
    
    
    
89. YANG H, Zhou J, Li D, Zhou S, et al
    The inhibitory role of microRNA-141-3p in human cutaneous melanoma growth and metastasis through the fibroblast growth factor 13-mediated mitogen-activated protein kinase axis.
    Melanoma Res. 2023 Mar 21. doi: 10.1097/CMR.0000000000000873.
    PubMed     Abstract available
    
    
    
90. BOILEAU M, Templier C, Massip E, Dehoux C, et al
    Description of supportive care and feasibility of physical exercise program to improve quality of life in advanced melanoma patients.
    Melanoma Res. 2023 Mar 17. doi: 10.1097/CMR.0000000000000889.
    PubMed     Abstract available
    
    
    
91. PIGNE T, Levy M, Ducharme O, Dutriaux C, et al
    Real-life use of trametinib after immunotherapy failure in BRAF wild-type advanced melanoma.
    Melanoma Res. 2023 Mar 15. doi: 10.1097/CMR.0000000000000884.
    PubMed     Abstract available
    
    
    
92. BOILEAU M, Descarpentries C, Delzenne G, Trentesaux V, et al
    Clinical response under MEK inhibitor alone in metastatic melanoma with a novel fusion involving the RAF1 gene.
    Melanoma Res. 2023 Mar 3. doi: 10.1097/CMR.0000000000000882.
    PubMed     Abstract available
    
    
    
93. JASSO-SOSA VY, Lino-Silva LS, Escobar-Jimenez MG, Galvan-Bustillos JR, et al
    Prognosis of polypoid melanoma: a comparative study with non-polypoid melanomas.
    Melanoma Res. 2023 Mar 3. doi: 10.1097/CMR.0000000000000886.
    PubMed     Abstract available
    
    
    
94. BERBERICH C, Mustafa M, Zhuwu Y, Gaa J, et al
    The influence of metastatic patterns and tumor load on therapeutic efficacy of immunotherapy in patients with metastatic melanoma as determined by quantitative PET-parameters using [18F]-fluorodeoxyglucose PET/computed tomography.
    Melanoma Res. 2023 Mar 3. doi: 10.1097/CMR.0000000000000883.
    PubMed     Abstract available
    
    
    February 2023
95. KOMULAINEN J, Siiskonen H, Haimakainen S, Kanasuo E, et al
    Patients with a history of atopy have fewer cutaneous melanomas than those without atopy: a cross-sectional study in 496 patients at risk of skin cancers.
    Melanoma Res. 2023 Feb 28:e000887. doi: 10.1097/CMR.0000000000000887.
    PubMed     Abstract available
    
    
    
96. GORLOV IP, Conway K, Edmiston SN, Parrish EA, et al
    Methylation of nonessential genes in cutaneous melanoma - Rule Out hypothesis.
    Melanoma Res. 2023 Feb 20:e000881. doi: 10.1097/CMR.0000000000000881.
    PubMed     Abstract available
    
    
    
97. JANSSEN L, Van Kelst S, De Smedt J, Terrasson J, et al
    Preoperative assessment of cutaneous melanoma thickness by multispectral dermoscopy.
    Melanoma Res. 2023;33:84-86.
    PubMed     Abstract available
    
    
    
98. HUO CW, Gunadasa I, Gkolia P, Shackleton M, et al
    Immune-related adverse events are associated with therapeutic efficacy of immunotherapy in patients with melanoma brain metastases.
    Melanoma Res. 2023;33:58-65.
    PubMed     Abstract available
    
    
    
99. BETOF WARNER A, Tarhini A, Kang B, Nakasato A, et al
    Real-world outcomes of different lines and sequences of treatment in BRAF-positive advanced melanoma patients.
    Melanoma Res. 2023;33:38-49.
    PubMed     Abstract available
    
    
    
100. LI C, Ye Z, Wang Y, Wang G, et al
     High expression of GRB2 associated binding protein 3 mRNA predicts positive prognosis in melanoma.
     Melanoma Res. 2023;33:27-37.
     PubMed     Abstract available
     
     
     
101. RAO D, Lacroix R, Rooker A, Gomes T, et al
     MeVa2.1.dOVA and MeVa2.2.dOVA: two novel BRAFV600E-driven mouse melanoma cell lines to study tumor immune resistance.
     Melanoma Res. 2023;33:12-26.
     PubMed     Abstract available
     
     
     
102. ZAKRIA D, Brownstone N, Han J, Owji S, et al
     Electrical impedance spectroscopy significantly enhances correct biopsy choice for pigmented skin lesions beyond clinical evaluation and dermoscopy.
     Melanoma Res. 2023;33:80-83.
     PubMed     Abstract available
     
     
     
103. HOFFMANN F, Frohlich A, Sirokay J, de Vos L, et al
     DNA methylation of GITR, OX40, 4-1BB, CD27, and CD40 correlates with BAP1 aberrancy and prognosis in uveal melanoma.
     Melanoma Res. 2023 Feb 1. doi: 10.1097/CMR.0000000000000879.
     PubMed     Abstract available
     
     
     January 2023
104. KOWALIK A, Karpinski P, Markiewicz A, Orlowska-Heitzman J, et al
     Molecular profiling of primary uveal melanoma: results of a Polish cohort.
     Melanoma Res. 2023 Jan 30. doi: 10.1097/CMR.0000000000000874.
     PubMed     Abstract available
     
     
     
105. PINTO C, Aluai-Cunha C, Santos A
     The human and animals' malignant melanoma: comparative tumor models and the role of microbiome in dogs and humans.
     Melanoma Res. 2023 Jan 20:CMR.0000000000000880.
     PubMed     Abstract available
     
     
     December 2022
106. KANASUO E, Siiskonen H, Haimakainen S, Komulainen J, et al
     Regular use of vitamin D supplement is associated with fewer melanoma cases compared to non-use: a cross-sectional study in 498 adult subjects at risk of skin cancers.
     Melanoma Res. 2022 Dec 28:CMR.0000000000000870.
     PubMed     Abstract available
     
     
     
107. GAJANAN K, Daga K, Mullan D, Kosutic D, et al
     New technique for in-continuity axillary and supraclavicular lymphadenectomy for advanced metastatic melanoma using intraoperative image guidance: a case report.
     Melanoma Res. 2022 Dec 28. doi: 10.1097/CMR.0000000000000868.
     PubMed     Abstract available
     
     
     
108. GARGIULO L, Ibba L, Valenti M, Costanzo A, et al
     Pembrolizumab-induced plaque psoriasis successfully treated with risankizumab in a patient with stage IV cutaneous melanoma.
     Melanoma Res. 2022 Dec 27:CMR.0000000000000875.
     PubMed     Abstract available
     
     
     
109. 
     Prognostic biomarkers in uveal melanoma: evidence for a stem cell-like phenotype associated with metastasis: Erratum.
     Melanoma Res. 2022;32:492.
     PubMed    
     
     
     
110. BORGOGNONI L, Crocetti E, Sestini S, Brandani P, et al
     The importance of mitosis >/=2 in selecting patients with T1 cutaneous melanomas for sentinel lymph node biopsy.
     Melanoma Res. 2022;32:469-476.
     PubMed     Abstract available
     
     
     
111. SMITH JL, Menzies AM, Cohen JV, Mut-Lloret M, et al
     Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case series.
     Melanoma Res. 2022;32:451-459.
     PubMed     Abstract available
     
     
     November 2022
112. FRANKE V, Stahlie EHA, Klop WMC, Zuur CL, et al
     Talimogene laherparepvec monotherapy for head and neck melanoma patients.
     Melanoma Res. 2022 Nov 29. doi: 10.1097/CMR.0000000000000866.
     PubMed     Abstract available
     
     
     
113. TRIVEDI DB, Aldulaimi N, Karydis I, Wheater M, et al
     Liver resection for metastatic uveal melanoma: experience from a supra-regional centre and review of literature.
     Melanoma Res. 2022 Nov 21. doi: 10.1097/CMR.0000000000000867.
     PubMed     Abstract available
     
     
     
114. KARTOLO A, Tong J, Yeung C, Kuksis M, et al
     Survivals following discontinuation of PD-1 inhibitor treatment in advanced melanoma patients.
     Melanoma Res. 2022 Nov 16. pii: 00008390-990000000-00046.
     PubMed     Abstract available
     
     
     October 2022
115. RAMOS R, Cabre E, Vinyals A, Lorenzo D, et al
     Orthotopic murine xenograft model of uveal melanoma with spontaneous liver metastasis.
     Melanoma Res. 2022 Oct 28. pii: 00008390-990000000-00043.
     PubMed     Abstract available
     
     
     
116. SHUI IM, Scherrer E, Frederickson A, Li JW, et al
     Resistance to anti-PD1 therapies in patients with advanced melanoma: systematic literature review and application of the Society for Immunotherapy of Cancer immunotherapy resistance taskforce anti-PD1 resistance definitions.
     Melanoma Res. 2022 Oct 7. pii: 00008390-990000000-00037.
     PubMed     Abstract available
     
     
     
117. CAVALLO F, Roccuzzo G, Merli M, Avallone G, et al
     BRCA1-associated protein 1 c.368delG mutation leads to the development of multiple BAPomas and cutaneous melanomas: a novel pathogenic variant in BRCA1-associated protein tumor predisposition syndrome.
     Melanoma Res. 2022;32:390-392.
     PubMed    
     
     
     
118. BRUGUES A, Ribero S, Pastorino C, Iglesias P, et al
     Challenging pigmented lesions in melanoma patients during checkpoint-inhibitors therapy.
     Melanoma Res. 2022;32:388-390.
     PubMed    
     
     
     September 2022
119. EDMONDS NL, Flores SE, Mahmutovic A, Young SJ, et al
     CD103 and periplakin are potential biomarkers for response of metastatic melanoma to pembrolizumab.
     Melanoma Res. 2022 Sep 28. pii: 00008390-990000000-00041.
     PubMed     Abstract available
     
     
     
120. FADADU RP, Wei ML
     Ultraviolet A radiation exposure and melanoma: a review.
     Melanoma Res. 2022 Sep 20. pii: 00008390-990000000-00039.
     PubMed     Abstract available
     
     
     
121. MENNENS F, Van Herck Y, Sciot R, Bempt IV, et al
     Melanoma cell plasticity poses diagnostic challenges: a case series.
     Melanoma Res. 2022 Sep 20. pii: 00008390-990000000-00038.
     PubMed     Abstract available
     
     
     
122. TEJEDOR I, Tedbirt B, Carvalho P, Duval-Modeste AB, et al
     Successful use of rituximab for refractory hemophagocytic lymphohistiocytosis in a melanoma patient treated with targeted therapy.
     Melanoma Res. 2022 Sep 20. pii: 00008390-990000000-00036.
     PubMed     Abstract available
     
     
     
123. SCHILLER T, Vaisbuch E, Zornitzki T, Kirzhner A, et al
     Adrenal metastatic melanoma first identified during pregnancy: a diagnostic challenge.
     Melanoma Res. 2022 Sep 13. pii: 00008390-990000000-00035.
     PubMed     Abstract available
     
     
     
124. YIN L, Liu X, Wu J, Yang J, et al
     LS-007 inhibits melanoma growth via inducing apoptosis and cell cycle arrest and regulating macrophage polarization.
     Melanoma Res. 2022 Sep 9. pii: 00008390-990000000-00034.
     PubMed     Abstract available
     
     
     August 2022
125. COMITO F, Aprile M, Pagani R, Siepe G, et al
     Clinical characteristics and treatment outcomes of non-V600 E/K BRAF mutant melanoma patients: a single-institution experience.
     Melanoma Res. 2022 Aug 29. pii: 00008390-990000000-00033.
     PubMed     Abstract available
     
     
     
126. ZHENG YJ, Ho W, Sanlorenzo M, Vujic I, et al
     Melanoma risk during immunomodulating treatment.
     Melanoma Res. 2022 Aug 22. pii: 00008390-990000000-00032.
     PubMed     Abstract available
     
     
     
127. GRACIA-DARDER I, Carrera C, Alamon-Reig F, Puig S, et al
     Vitamin D deficiency in melanoma patients is associated with worse overall survival: a retrospective cohort study.
     Melanoma Res. 2022 Aug 17. pii: 00008390-990000000-00030.
     PubMed     Abstract available
     
     
     
128. BROWNSTONE N, Marson JW, Zakria D, Farberg A, et al
     Variance from published guidelines and changes in temporal trends in the management of cutaneous malignant melanoma: a 5-year update.
     Melanoma Res. 2022 Aug 17. pii: 00008390-990000000-00031.
     PubMed     Abstract available
     
     
     
129. LASOCKI A, McArthur GA
     Correlation of MRI signal characteristics of intracranial melanoma metastases with BRAF mutation status.
     Melanoma Res. 2022 Aug 17. pii: 00008390-990000000-00029.
     PubMed     Abstract available
     
     
     July 2022
130. MANGANA J, Zihler D, Bossart S, Bronnimann D, et al
     Treatment reality of patients with BRAF-mutant advanced/metastatic melanoma in Switzerland in the era of choice.
     Melanoma Res. 2022 Jul 20. pii: 00008390-990000000-00028.
     PubMed     Abstract available
     
     
     
131. BUJA A, Rugge M, De Luca G, Zorzi M, et al
     Clinical performance indicators for monitoring the management of cutaneous melanoma: a population-based perspective.
     Melanoma Res. 2022 Jul 19. pii: 00008390-990000000-00027.
     PubMed     Abstract available
     
     
     
132. FILIPPI F, Serra N, Vigano P, Boeri L, et al
     Fertility preservation for patients with melanoma.
     Melanoma Res. 2022 Jul 19. pii: 00008390-990000000-00025.
     PubMed     Abstract available
     
     
     
133. OSTOJIC N, Radevic T, Kandolf Sekulovic L, Djordjevic B, et al
     Polymorphisms in toll-like receptor 3 and 4 genes as prognostic and outcome biomarkers in melanoma patients.
     Melanoma Res. 2022 Jul 19. pii: 00008390-990000000-00026.
     PubMed     Abstract available
     
     
     
134. KLEE G, Hagelstein V, Kurzhals JK, Zillikens D, et al
     Dacarbazine in the management of metastatic melanoma in the era of immune checkpoint therapy: a valid option or obsolete?
     Melanoma Res. 2022 Jul 19. pii: 00008390-990000000-00024.
     PubMed     Abstract available
     
     
     
135. LINO-SILVA LS, Zepeda-Najar C, Caro-Sanchez CH, Herrera-Gomez A, et al
     Prognostic significance of tumor budding in melanoma.
     Melanoma Res. 2022 Jul 1. pii: 00008390-990000000-00023.
     PubMed     Abstract available
     
     
     June 2022
136. GONZALEZ-BARRALLO I, Castellon Rubio VE, Medina J, Espana S, et al
     Safety of combining dabrafenib plus trametinib in elderly BRAF V600 mutation-positive advanced melanoma patients: real-world data analysis of Spanish patients (ELDERLYMEL).
     Melanoma Res. 2022 Jun 27. pii: 00008390-990000000-00022.
     PubMed     Abstract available
     
     
     
137. TASKAYNATAN H, Gunenc D, On S, Mizrak A, et al
     Immunotherapy-induced granulomatous reaction in patients with melanoma.
     Melanoma Res. 2022 Jun 23. pii: 00008390-990000000-00021.
     PubMed     Abstract available
     
     
     
138. YU IS, Wee K, Williamson L, Titmuss E, et al
     Exceptional response to combination ipilimumab and nivolumab in metastatic uveal melanoma: Insights from genomic analysis.
     Melanoma Res. 2022 Jun 17. pii: 00008390-990000000-00020.
     PubMed     Abstract available
     
     
     
139. SIZOVA M, Camacho V, Sampedro F, Sabate-Llobera A, et al
     Brain metabolic changes in patients with disseminated malignant melanoma under immunotherapy.
     Melanoma Res. 2022 Jun 15. pii: 00008390-990000000-00019.
     PubMed     Abstract available
     
     
     
140. WEBER JS, Levinson BA, Laino AS, Pavlick AC, et al
     Clinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III/IV melanoma.
     Melanoma Res. 2022 Jun 9. pii: 00008390-990000000-00018.
     PubMed     Abstract available
     
     
     
141. ISMAIL RK, Suijkerbuijk KPM, de Boer A, van Dartel M, et al
     Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors.
     Melanoma Res. 2022 Jun 6. pii: 00008390-990000000-00017.
     PubMed     Abstract available
     
     
     
142. INGEN-HOUSZ-ORO S, Milpied B, Badrignans M, Carrera C, et al
     Severe blistering eruptions induced by immune checkpoint inhibitors: a multicentre international study of 32 cases.
     Melanoma Res. 2022;32:205-210.
     PubMed     Abstract available
     
     
     May 2022
143. RODRIGUEZ CASTELLS M, Galisteo Lencastre Veiga C, Fernandez-Morales LA, Ejarque Martinez C, et al
     Immune-mediated necrotizing myopathy with anti-signal recognition particle antibodies, in a patient with melanoma treated with BRAF/MEK inhibitors.
     Melanoma Res. 2022 May 30. pii: 00008390-990000000-00016.
     PubMed     Abstract available
     
     
     
144. MEYER N, Perol D, Duval-Modeste AB, El Adaoui L, et al
     Survival in adult patients with BRAFV600 mutation-positive advanced melanoma: a noninterventional ambispective study of patients with cobimetinib combined with vemurafenib during the French early access program: MELANIS study.
     Melanoma Res. 2022 May 27. pii: 00008390-990000000-00015.
     PubMed     Abstract available
     
     
     
145. MADISON CJ, Heinrich MC, Thompson RF, Yu WY, et al
     Statin use is associated with improved overall survival in patients with melanoma.
     Melanoma Res. 2022 May 13. pii: 00008390-990000000-00012.
     PubMed     Abstract available
     
     
     
146. LI AT, Miin Yip J, Choksi H, London K, et al
     Lack of association between anatomical sites of scalp melanomas and brain metastases does not support direct vascular spread.
     Melanoma Res. 2022 May 13. pii: 00008390-990000000-00013.
     PubMed     Abstract available
     
     
     
147. DIKA E, Lambertini M, Lauriola M, Veronesi G, et al
     Female melanoma and estrogen receptors expression: an immunohistochemical pilot study.
     Melanoma Res. 2022 May 13. pii: 00008390-990000000-00010.
     PubMed     Abstract available
     
     
     
148. SEYED JAFARI SM, Mazinani M, Beutler-Minth V, Lamos C, et al
     Noncontrast-enhanced 3-Tesla MRI using surface coil as a complementary test for assessment of distribution and depth of locoregional cutaneous metastases of malignant melanoma.
     Melanoma Res. 2022 May 13. pii: 00008390-990000000-00011.
     PubMed     Abstract available
     
     
     
149. HANNARICI Z, Yilmaz A, Buyukbayram ME, Tekin SB, et al
     Reply to John L. Frater's letter to the editor entitled Use of laboratory hematology data in melanoma research: comments on 'A novel prognostic biomarker for cutaneous malignant melanoma: red cell distribution width (RDW) to lymphocyte ratio'.
     Melanoma Res. 2022 May 13. pii: 00008390-990000000-00014.
     PubMed    
     
     
     
150. WOLFE Z, Friedland JC, Ginn S, Blackham A, et al
     Case report: response to the ERK1/2 inhibitor ulixertinib in BRAF D594G cutaneous melanoma.
     Melanoma Res. 2022 May 12. pii: 00008390-990000000-00009.
     PubMed     Abstract available
     
     
     April 2022
151. MULDER EEAP, Damman J, Verver D, van der Veldt AAM, et al
     Histopathological and immunological spectrum in response evaluation of talimogene laherparepvec treatment and correlation with durable response in patients with cutaneous melanoma.
     Melanoma Res. 2022 Apr 21. pii: 00008390-990000000-00008.
     PubMed     Abstract available
     
     
     
152. SCHMELTER V, Hofmann T, Schneider F, Weber C, et al
     Robotic CyberKnife radiosurgery for small choroidal melanomas.
     Melanoma Res. 2022 Apr 8. pii: 00008390-990000000-00007.
     PubMed     Abstract available
     
     
     
153. FRATER JL
     Use of laboratory hematology data in melanoma research: comments on "A novel prognostic biomarker for cutaneous malignant melanoma: red cell distribution width (RDW) to lymphocyte ratio" Melanoma Res 2021; 31:566-574.
     Melanoma Res. 2022;32:136.
     PubMed    
     
     
     
154. O'DAY R, Grantham M, Thaung C, Szlosarek P, et al
     Tetrasomy of chromosomes 3 and 8 in a young male with choroidal melanoma.
     Melanoma Res. 2022;32:134-135.
     PubMed    
     
     
     
155. GAMBICHLER T, Susok L
     Uncomplicated pregnancy and delivery under ongoing nivolumab therapy for metastatic melanoma.
     Melanoma Res. 2022;32:132-133.
     PubMed    
     
     
     
156. FARRELL J, Stewart TJ, Rosen R
     Study of clinical characteristics and risk factors for amelanotic/hypomelanotic melanoma in an Australian cohort.
     Melanoma Res. 2022;32:130-131.
     PubMed    
     
     
     
157. MIECZKOWSKA K, Jacob J, Paoluzzi L, Papalezova KT, et al
     Documenting the histologic response of metastatic melanoma to combination therapy with BRAF and MEK inhibitors.
     Melanoma Res. 2022;32:128-129.
     PubMed    
     
     
     
158. KROMER C, Vlahova LD, Julius K, Schnabel V, et al
     Response of metastatic melanoma with a rare BRAF V600K mutation to dabrafenib and trametinib.
     Melanoma Res. 2022;32:124-127.
     PubMed    
     
     
     
159. MODI S, Gibson T, Vigneswaran G, Patel S, et al
     Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma.
     Melanoma Res. 2022;32:103-111.
     PubMed     Abstract available
     
     
     
160. WISCO OJ, Marson JW, Litchman GH, Brownstone N, et al
     Improved cutaneous melanoma survival stratification through integration of 31-gene expression profile testing with the American Joint Committee on Cancer 8th Edition Staging.
     Melanoma Res. 2022;32:98-102.
     PubMed     Abstract available
     
     
     
161. WACH MM, Subjeck JR, Wang XY, Repasky E, et al
     Recombinant human Hsp110-gp100 chaperone complex vaccine is nontoxic and induces response in advanced stage melanoma patients.
     Melanoma Res. 2022;32:88-97.
     PubMed     Abstract available
     
     
     
162. HILL MV, Vidri RJ, Deng M, Handorf E, et al
     Real-world frequency of BRAF testing and utilization of therapies in patients with advanced melanoma.
     Melanoma Res. 2022;32:79-87.
     PubMed     Abstract available
     
     
     
163. YIN G, Guo W, Huang Z, Chen X, et al
     Efficacy of radiotherapy combined with immune checkpoint inhibitors in patients with melanoma: a systemic review and meta-analysis.
     Melanoma Res. 2022;32:71-78.
     PubMed     Abstract available
     
     
     March 2022
164. AWADA G, Schwarze JK, Tijtgat J, Fasolino G, et al
     A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors.
     Melanoma Res. 2022 Mar 29. pii: 00008390-990000000-00001.
     PubMed     Abstract available
     
     
     
165. WANG CY, Zoungas S, Voskoboynik M, Mar V, et al
     Cardiovascular disease and malignant melanoma.
     Melanoma Res. 2022 Mar 29. pii: 00008390-990000000-00004.
     PubMed     Abstract available
     
     
     
166. YANO M, Nasu K, Yasuda M, Katoh T, et al
     Clinicopathological features and programmed death-ligand 1 immunohistochemical expression in a multicenter cohort of uterine and ovarian melanomas: a retrospective study in Japan (KCOG-G1701s).
     Melanoma Res. 2022 Mar 29. pii: 00008390-990000000-00002.
     PubMed     Abstract available
     
     
     
167. LAUWYCK J, Schreuer M, Meric de Bellefon L, Van Erps J, et al
     Severe treatment-induced inflammatory polyarthritis in advanced melanoma patients: 2 case reports.
     Melanoma Res. 2022 Mar 29. pii: 00008390-990000000-00003.
     PubMed     Abstract available
     
     
     
168. FU XL, Feng LP, Yu HR, Du L, et al
     Efficacy and safety of angiogenesis inhibitors in melanoma: a meta-analysis of seven randomized controlled trials.
     Melanoma Res. 2022 Mar 29. pii: 00008390-990000000-00005.
     PubMed     Abstract available
     
     
     
169. PEDERSEN S, Moller S, Donia M, Persson GF, et al
     Real-world data on melanoma brain metastases and survival outcome.
     Melanoma Res. 2022 Mar 7. pii: 00008390-900000000-98978.
     PubMed     Abstract available
     
     
     
170. XU J, Ou R, Nie G, Wen J, et al
     LINC01063 functions as an oncogene in melanoma through regulation of miR-5194-mediated SOX12 expression.
     Melanoma Res. 2022 Mar 7. pii: 00008390-900000000-98977.
     PubMed     Abstract available
     
     
     
171. MCCANN B, Higgins M, Kok DL, Hong W, et al
     Long-term control of melanoma adrenal metastasis treated with radiotherapy.
     Melanoma Res. 2022 Mar 7. pii: 00008390-900000000-98976.
     PubMed     Abstract available
     
     
     February 2022
172. HOTZ MJ, O'Halloran EA, Hill MV, Hayden K, et al
     Tumor mutational burden and somatic mutation status to predict disease recurrence in advanced melanoma.
     Melanoma Res. 2022 Feb 24. pii: 00008390-900000000-98979.
     PubMed     Abstract available
     
     
     
173. ZHOU L, Yang Y, Si L, Chi Z, et al
     Phase II study of apatinib combined with temozolomide in patients with advanced melanoma after failure of immunotherapy.
     Melanoma Res. 2022 Feb 20. pii: 00008390-900000000-98980.
     PubMed     Abstract available
     
     
     
174. STECKLER AM, Francis JH, Shoushtari AN, Abramson DH, et al
     Uveal melanoma metastatic at initial diagnosis: a case series.
     Melanoma Res. 2022 Feb 11. pii: 00008390-900000000-98981.
     PubMed     Abstract available
     
     
     
175. DUNJIC M, Lukic N, Djordjevic B, Uzelac B, et al
     GLI-1 polymorphisms of Hedgehog pathway as novel risk and prognostic biomarkers in melanoma patients.
     Melanoma Res. 2022;32:11-17.
     PubMed     Abstract available
     
     
     
176. LEE J, Jin YJ, Lee MS, Lee H, et al
     Macrophage inhibitory cytokine-1 produced by melanoma cells contributes to melanoma tumor growth and metastasis in vivo by enhancing tumor vascularization.
     Melanoma Res. 2022;32:1-10.
     PubMed     Abstract available
     
     
     
177. KIM YH, Kim Y, Park TJ, Kang HY, et al
     Ponatinib-induced eruptive nevi and melanocytic proliferation.
     Melanoma Res. 2022;32:59-62.
     PubMed     Abstract available
     
     
     December 2021
178. SUN S, Shi R, Xu L, Sun F, et al
     Identification of heterogeneity and prognostic key genes associated with uveal melanoma using single-cell RNA-sequencing technology.
     Melanoma Res. 2021 Dec 3. pii: 00008390-900000000-98987.
     PubMed     Abstract available
     
     
     
179. JANOWSKA A, Oranges T, Iannone M, Davini G, et al
     Ultra-high-frequency ultrasound monitoring of melanomas arising in congenital melanocytic nevi: a case series.
     Melanoma Res. 2021;31:561-565.
     PubMed     Abstract available
     
     
     
180. YE JY, Yu C, Husman T, Chen B, et al
     Novel strategy for applying hierarchical density-based spatial clustering of applications with noise towards spectroscopic analysis and detection of melanocytic lesions.
     Melanoma Res. 2021;31:526-532.
     PubMed     Abstract available
     
     
     November 2021
181. CAKIR OO, Pozzi E, Castiglione F, Freeman A, et al
     Clinical features, molecular characteristics and surgical management of primary penile mucosal melanoma based on the European Association of Urology Penile Cancer Guidelines.
     Melanoma Res. 2021 Nov 24. pii: 00008390-900000000-98989.
     PubMed     Abstract available
     
     
     
182. DAVIDSON TM, Markovic SN, Dimou A
     The immunologic balance: three cases of rituximab-associated melanoma.
     Melanoma Res. 2021 Nov 15. pii: 00008390-900000000-98990.
     PubMed     Abstract available
     
     
     
183. SAH VR, Karlsson J, Jespersen H, Lindberg MF, et al
     Epigenetic therapy to enhance therapeutic effects of PD-1 inhibition in therapy-resistant melanoma.
     Melanoma Res. 2021 Nov 5. pii: 00008390-900000000-98991.
     PubMed     Abstract available
     
     
     
184. DE GIORGI V, Gemignani A, Scarfi F, Trane L, et al
     Eruptive melanocytic nevi in a patient with amelanotic melanoma: a paraneoplastic phenomenon?
     Melanoma Res. 2021 Nov 1. pii: 00008390-900000000-98993.
     PubMed     Abstract available
     
     
     
185. JAN WILLEM RAUWERDINK D, van Persijn van Meerten E, van der Hage J, Kapiteijn E, et al
     Management of heterogeneous tumor response patterns to immunotherapy in patients with metastatic melanoma.
     Melanoma Res. 2021 Nov 1. pii: 00008390-900000000-98992.
     PubMed     Abstract available
     
     
     October 2021
186. PARIETTI M, Marra E, Ribero S, Abate SO, et al
     Leptomeningeal dissemination as a first sign of progression in metastatic melanoma: a diagnostic lesson.
     Melanoma Res. 2021 Oct 22. pii: 00008390-900000000-98994.
     PubMed     Abstract available
     
     
     
187. MOGLIA A, Cerri A, Moglia A, Berchiolli R, et al
     Machine learning for the identification of decision boundaries during the transition from radial to vertical growth phase superficial spreading melanomas.
     Melanoma Res. 2021 Oct 21. pii: 00008390-900000000-98995.
     PubMed     Abstract available
     
     
     
188. MANTIA CM, Werner L, Stwalley B, Ritchings C, et al
     Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors.
     Melanoma Res. 2021 Oct 20. pii: 00008390-900000000-98997.
     PubMed     Abstract available
     
     
     
189. GARGIULO L, Chiara Tronconi M, Grimaudo MS, Pavia G, et al
     Connective tissue panniculitis and vitiligo in a with patient stage IV melanoma achieving complete response to dabrafenib and trametinib combination therapy.
     Melanoma Res. 2021 Oct 5. pii: 00008390-900000000-98999.
     PubMed     Abstract available
     
     
     
190. JANOWSKA A, Oranges T, Iannone M, Romanelli M, et al
     Seborrheic keratosis-like melanoma: a diagnostic challenge.
     Melanoma Res. 2021;31:407-412.
     PubMed     Abstract available
     
     
     
191. TULOKAS SKA, Kohtamaki LM, Makela SP, Juteau S, et al
     Isolated limb perfusion with melphalan as treatment for regionally advanced melanoma of the limbs: results of 60 patients treated in Finland during 2007-2018.
     Melanoma Res. 2021;31:456-463.
     PubMed     Abstract available
     
     
     September 2021
192. HANNARICI Z, Yilmaz A, Buyukbayram ME, Tekin SB, et al
     A novel prognostic biomarker for cutaneous malignant melanoma: red cell distribution width (RDW) to lymphocyte ratio.
     Melanoma Res. 2021 Sep 23. pii: 00008390-900000000-99001.
     PubMed     Abstract available
     
     
     
193. FIDANZI C, Manzo Margiotta F, Spinelli C, Janowska A, et al
     Risk factors in pediatric melanoma: a retrospective study of 39 cases.
     Melanoma Res. 2021 Sep 23. pii: 00008390-900000000-99000.
     PubMed     Abstract available
     
     
     
194. AMAGAI R, Muto Y, Kato H, Matsushita S, et al
     Retrospective analysis of adjuvant therapy using dabrafenib plus trametinib in Japanese patients with advanced melanoma: analysis of 36 cases.
     Melanoma Res. 2021 Sep 13. pii: 00008390-900000000-99006.
     PubMed     Abstract available
     
     
     
195. FONSECA M, Soares R, Coelho P
     Lower melanoma pulmonary metastatic burden in obese mice: role of FGF-21.
     Melanoma Res. 2021 Sep 13. pii: 00008390-900000000-99005.
     PubMed     Abstract available
     
     
     
196. LAN S, Cui Z, Yin Q, Liu Z, et al
     Prospective study of clinical characteristics of melanoma patients with retinopathy caused by a high-dose interferon alpha-2b.
     Melanoma Res. 2021 Sep 13. pii: 00008390-900000000-99004.
     PubMed     Abstract available
     
     
     
197. CHEN M, Li Q, Chen W, Bi J, et al
     Diagnostic and prognostic value of Beclin 1 expression in melanoma: a meta-analysis.
     Melanoma Res. 2021 Sep 7. pii: 00008390-900000000-99008.
     PubMed     Abstract available
     
     
     
198. SHI CJ, Xu SM, Han Y, Zhou R, et al
     Targeting cyclin-dependent kinase 4/6 as a therapeutic approach for mucosal melanoma.
     Melanoma Res. 2021 Sep 3. pii: 00008390-900000000-99009.
     PubMed     Abstract available
     
     
     August 2021
199. AVALLONE G, Astrua C, Fava P, Tonella L, et al
     Acute appendicitis secondary to desmoplastic melanoma metastasis in immune-checkpoint inhibitors era.
     Melanoma Res. 2021 Aug 27. pii: 00008390-900000000-99010.
     PubMed    
     
     
     
200. FARINAZZO E, Zelin E, Agozzino M, Papa G, et al
     Regression of nevi, vitiligo-like depigmentation and halo phenomenon may indicate response to immunotherapy and targeted therapy in melanoma.
     Melanoma Res. 2021 Aug 23. pii: 00008390-900000000-99016.
     PubMed     Abstract available
     
     
     
201. GULIKERS JL, Croes S, Schreurs MJW, Litjens EJR, et al
     Nivolumab exposure in a hemodialysis patient with metastatic melanoma.
     Melanoma Res. 2021 Aug 23. pii: 00008390-900000000-99015.
     PubMed     Abstract available
     
     
     
202. INDINI A, Costa S, Ierardi AM, Rijavec E, et al
     COVID-19 vaccination mimicking lymph-node progression in a patient with melanoma: a case report.
     Melanoma Res. 2021 Aug 23. pii: 00008390-900000000-99014.
     PubMed     Abstract available
     
     
     
203. SCHNEIDER S, Alezra E, Yacoub M, Ducharme O, et al
     Aseptic cystitis induced by nivolumab and ipilimumab combination for metastatic melanoma.
     Melanoma Res. 2021 Aug 23. pii: 00008390-900000000-99013.
     PubMed     Abstract available
     
     
     
204. CHO KK, Cust AE, Foo YM, Long GV, et al
     Metastatic acral melanoma treatment outcomes: a systematic review and meta-analysis.
     Melanoma Res. 2021 Aug 23. pii: 00008390-900000000-99012.
     PubMed     Abstract available
     
     
     
205. SILVA CTX, Saddi VA, Silva KSFE, Sugita DM, et al
     Expression of the cancer stem cell marker OCT4 is associated with worse prognosis and survival in cutaneous melanoma.
     Melanoma Res. 2021 Aug 23. pii: 00008390-900000000-99011.
     PubMed     Abstract available
     
     
     
206. GE Y, Che X, Gao X, Zhao S, et al
     Combination of radiotherapy and targeted therapy for melanoma brain metastases: a systematic review.
     Melanoma Res. 2021 Aug 17. pii: 00008390-900000000-99017.
     PubMed     Abstract available
     
     
     
207. CULLEN GD, Finnes HD, Markovic SN, Volcheck GW, et al
     Successful encorafenib desensitization in a patient with recurrent metastatic melanoma.
     Melanoma Res. 2021;31:402-404.
     PubMed     Abstract available
     
     
     
208. ADAMS AM, Chick RC, Vreeland TJ, Clifton GT, et al
     Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma.
     Melanoma Res. 2021;31:378-388.
     PubMed     Abstract available
     
     
     
209. XIAO M, Tang N, Yan Y, Li Z, et al
     Knockdown of enhancer of rudimentary homolog expression attenuates proliferation, cell cycle and apoptosis of melanoma cells.
     Melanoma Res. 2021;31:309-318.
     PubMed     Abstract available
     
     
     
210. PIKKEL YY, Duek OS, Ben Naftali Y, Link Y, et al
     Hidden in plain sight: the (other) danger of COVID-19.
     Melanoma Res. 2021;31:389-392.
     PubMed     Abstract available
     
     
     July 2021
211. KLEE G, Kurzhals J, Hagelstein V, Zillikens D, et al
     Low-dose ipilimumab combined with anti-PD-1 immunotherapy in patients with metastatic melanoma following anti-PD-1 treatment failure.
     Melanoma Res. 2021 Jul 19. pii: 00008390-900000000-99021.
     PubMed     Abstract available
     
     
     
212. TORRICELLI C, Carron J, Carvalho BF, Macedo LT, et al
     Influence of IL1B (rs16944) and IL1R2 (rs4141134) polymorphisms on aggressiveness and prognosis of cutaneous melanoma.
     Melanoma Res. 2021 Jul 19. pii: 00008390-900000000-99020.
     PubMed     Abstract available
     
     
     
213. MONDAL SK, Whiteside TL
     Proteomic profiles of melanoma cell-derived exosomes in plasma: discovery of potential biomarkers of melanoma progression.
     Melanoma Res. 2021 Jul 19. pii: 00008390-900000000-99018.
     PubMed     Abstract available
     
     
     June 2021
214. SANGSTER AB, Chang-McDonald B, Patel J, Bockett N, et al
     Expression of cathepsins B and D by cancer stem cells in head and neck metastatic malignant melanoma.
     Melanoma Res. 2021 Jun 10. pii: 00008390-900000000-99027.
     PubMed     Abstract available
     
     
     
215. MANNING A, Rassie K, Rivalland G
     A case of hyperprolactinaemia in a patient with metastatic melanoma.
     Melanoma Res. 2021;31:277-279.
     PubMed     Abstract available
     
     
     
216. TIJTGAT J, Schwarze JK, Awada G, Neyns B, et al
     Sarcoid-like reaction in a BRAF V600E-mutated metastatic melanoma patient during treatment with BRAF/MEK-targeted therapy.
     Melanoma Res. 2021;31:272-276.
     PubMed     Abstract available
     
     
     
217. HOLSTEAD RG, Kartolo BA, Hopman WM, Baetz TD, et al
     Impact of the development of immune related adverse events in metastatic melanoma treated with PD -1 inhibitors.
     Melanoma Res. 2021;31:258-263.
     PubMed     Abstract available
     
     
     
218. FRELAU A, Jali E, Campillo-Gimenez B, Pracht M, et al
     Prognostic impact of thyroid dysfunctions on progression-free survival in patients with metastatic melanoma treated with anti-PD-1 antibodies.
     Melanoma Res. 2021;31:208-217.
     PubMed     Abstract available
     
     
     
219. SANCHEZ JN, Subramanian C, Chanda M, Shanguan G, et al
     A novel C-terminal Hsp90 inhibitor KU758 synergizes efficacy in combination with BRAF or MEK inhibitors and targets drug-resistant pathways in BRAF-mutant melanomas.
     Melanoma Res. 2021;31:197-207.
     PubMed     Abstract available
     
     
     May 2021
220. HE H, Qiao B, Guo S, Cui H, et al
     Induction of T helper 17 cell response by interleukin-7 in patients with primary cutaneous melanoma.
     Melanoma Res. 2021 May 28. pii: 00008390-900000000-99031.
     PubMed     Abstract available
     
     
     
221. KHULLAR K, Hanft S, Mehnert JM, Weiner JP, et al
     Complete response of brainstem metastasis in BRAF-mutated melanoma without stereotactic radiosurgery after initiation of encorafenib and binimetinib.
     Melanoma Res. 2021 May 28. pii: 00008390-900000000-99030.
     PubMed     Abstract available
     
     
     
222. LAUWYCK J, Beckwee A, Santens A, Schwarze JK, et al
     C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting.
     Melanoma Res. 2021 May 28. pii: 00008390-900000000-99028.
     PubMed     Abstract available
     
     
     
223. TACAR SY, Selcukbiricik F, Yilmaz M, Erturk K, et al
     Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study.
     Melanoma Res. 2021 May 25. pii: 00008390-900000000-99038.
     PubMed     Abstract available
     
     
     
224. WILSON T, Taylor H, Winter H, Herbert C, et al
     Sequential immunotherapy in melanoma: is it a realistic alternative to dual immunotherapy?
     Melanoma Res. 2021 May 25. pii: 00008390-900000000-99037.
     PubMed     Abstract available
     
     
     
225. HARDIE CM, Allouni A, Edwards S, Ahmed N, et al
     PET-CT for staging pT4b melanomas prior to sentinel lymph node biopsy: a 5-year review.
     Melanoma Res. 2021 May 25. pii: 00008390-900000000-99036.
     PubMed     Abstract available
     
     
     
226. READ RL, Thompson JF
     The role of regional chemotherapy for advanced limb melanoma in the era of potentially effective systemic therapies.
     Melanoma Res. 2021 May 25. pii: 00008390-900000000-99035.
     PubMed     Abstract available
     
     
     
227. ZHAO Y, Huang C
     The role of osteopontin in the development and metastasis of melanoma.
     Melanoma Res. 2021 May 25. pii: 00008390-900000000-99034.
     PubMed     Abstract available
     
     
     
228. MALISSEN N, Farvacque G, Duconseil P, Birnbaum DJ, et al
     Surgery of small bowel melanoma metastases in the era of efficient medical therapies: a retrospective cohort study.
     Melanoma Res. 2021 May 25. pii: 00008390-900000000-99033.
     PubMed     Abstract available
     
     
     
229. YANG LX, Guo HB, Liu SY, Feng HP, et al
     ETS1 promoted cell growth, metastasis and epithelial-mesenchymal transition process in melanoma by regulating miR-16-mediated SOX4 expression.
     Melanoma Res. 2021 May 25. pii: 00008390-900000000-99032.
     PubMed     Abstract available
     
     
     
230. WU X, Yan J, Yu J, Cheng Z, et al
     Clinical significance of CCNE1 copy number gain in acral melanoma patients.
     Melanoma Res. 2021 May 6. pii: 00008390-900000000-99040.
     PubMed     Abstract available
     
     
     
231. BONHOURE A, Henry L, Morille M, Aissaoui N, et al
     Melanotransferrin is efficiently sorted on the surface of exosomes secreted by melanoma cells.
     Melanoma Res. 2021 May 6. pii: 00008390-900000000-99039.
     PubMed     Abstract available
     
     
     April 2021
232. TREMBATH DG, Ivanova A, Krauze MT, Kirkwood JM, et al
     Melanoma-specific expression of the tumor suppressor proteins p16 and PTEN is a favorable prognostic factor in established melanoma brain metastases.
     Melanoma Res. 2021 Apr 12. pii: 00008390-900000000-99043.
     PubMed     Abstract available
     
     
     
233. LEENEMAN B, Blommestein HM, Coupe VMH, Hendriks MP, et al
     Real-world healthcare costs of localized and regionally advanced cutaneous melanoma in the Netherlands.
     Melanoma Res. 2021 Apr 12. pii: 00008390-900000000-99042.
     PubMed     Abstract available
     
     
     
234. MOSCHOS SJ, Eroglu Z, Khushalani NI, Kendra KL, et al
     Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922).
     Melanoma Res. 2021;31:162-172.
     PubMed     Abstract available
     
     
     March 2021
235. THOMPSON JF, Saw RPM, Dalton JM, Stretch JR, et al
     Treatment of in-transit melanoma metastases using intralesional PV-10.
     Melanoma Res. 2021 Mar 18. pii: 00008390-900000000-99046.
     PubMed     Abstract available
     
     
     
236. SHAH P, Punekar SR, Pavlick AC
     Response to immune checkpoint inhibitor rechallenge after high-grade immune related adverse events in patients with advanced melanoma.
     Melanoma Res. 2021 Mar 18. pii: 00008390-900000000-99045.
     PubMed     Abstract available
     
     
     
237. KOHTAMAKI LM, Hernberg M, Jaakkola M, Makela S, et al
     BRAF inhibitor treatment is feasible in the oldest-old advanced melanoma patients.
     Melanoma Res. 2021 Mar 5. pii: 00008390-900000000-99047.
     PubMed     Abstract available
     
     
     February 2021
238. WESTON GK, Jeong HS, Mu EW, Polsky D, et al
     Impact of COVID-19 on melanoma diagnosis.
     Melanoma Res. 2021 Feb 18. pii: 00008390-900000000-99056.
     PubMed    
     
     
     
239. LEJEUNE FJ, Storkus WJ, Riley PA
     Thirty years of therapeutic innovation in melanoma research.
     Melanoma Res. 2021 Feb 18. pii: 00008390-900000000-99055.
     PubMed    
     
     
     
240. OLOFSSON BAGGE R, Ny L, Ascierto PA, Hodi FS, et al
     The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials.
     Melanoma Res. 2021 Feb 18. pii: 00008390-900000000-99054.
     PubMed     Abstract available
     
     
     
241. SARKAR M, Bhuniya A, Ghosh S, Sarkar A, et al
     Neem leaf glycoprotein salvages T cell functions from Myeloid-derived suppressor cells-suppression by altering IL-10/STAT3 axis in melanoma tumor microenvironment.
     Melanoma Res. 2021 Feb 18. pii: 00008390-900000000-99052.
     PubMed     Abstract available
     
     
     
242. DOMINGUEZ-VARELA IA, Ancona-Lezama DA, Dalvin LA, Perez-Ramos EE, et al
     Choroidal melanoma treatment in times of coronavirus disease 2019.
     Melanoma Res. 2021 Feb 18. pii: 00008390-900000000-99051.
     PubMed    
     
     
     
243. KERTYS M, Grendar M, Horak V, Zidekova N, et al
     Metabolomic characterisation of progression and spontaneous regression of melanoma in the melanoma-bearing Libechov minipig model.
     Melanoma Res. 2021 Feb 18. pii: 00008390-900000000-99050.
     PubMed     Abstract available
     
     
     
244. ZHANG X, Su MW, Cheng Y, Martinka M, et al
     Immunohistochemistry analysis reveals lysyl oxidase-like 3 as a novel prognostic marker for primary melanoma.
     Melanoma Res. 2021 Feb 18. pii: 00008390-900000000-99049.
     PubMed     Abstract available
     
     
     
245. RANTALA ES, Kivela TT, Hernberg MM
     Impact of staging on survival outcomes: a nationwide real-world cohort study of metastatic uveal melanoma.
     Melanoma Res. 2021 Feb 15. pii: 00008390-900000000-99057.
     PubMed     Abstract available
     
     
     
246. MILLAN-ESTEBAN D, Garcia-Casado Z, Manrique-Silva E, Kumar R, et al
     KIT mutational status does not constitute an independent prognostic marker in cutaneous melanoma. A study on 688 Spanish patients.
     Melanoma Res. 2021;31:101-103.
     PubMed    
     
     
     
247. ISMAIL RK, Sikkes NO, Wouters MWJM, Hilarius DL, et al
     Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastases.
     Melanoma Res. 2021;31:58-66.
     PubMed     Abstract available
     
     
     January 2021
248. ZHANG T, Li Q, Wang Q, Wang H, et al
     Diagnostic and prognostic value of heat shock protein 90alpha in malignant melanoma.
     Melanoma Res. 2021 Jan 22. pii: 00008390-900000000-99059.
     PubMed     Abstract available
     
     
     
249. BENINATO T, Fuca G, Di Guardo L, Vetrano I, et al
     Immune-related Bell's palsy in melanoma patients treated with immune checkpoint inhibitors.
     Melanoma Res. 2021 Jan 22. pii: 00008390-900000000-99058.
     PubMed     Abstract available
     
     
     December 2020
250. LUO X, Xu Y, Li Y, Zhang G, et al
     BAP1 deletion abrogates growth and metastasis of murine cutaneous melanoma.
     Melanoma Res. 2020;Publish Ahead of Print.
     PubMed     Abstract available
     
     
     
251. ZAFAR FS, Richey P, Okereke U, Milhem M, et al
     Morphea following treatment with pembrolizumab for melanoma with metastatic lymph nodes: case report and review of literature.
     Melanoma Res. 2020;Publish Ahead of Print.
     PubMed     Abstract available
     
     
     
252. HOLMAN BN, Van Gulick RJ, Amato CM, MacBeth ML, et al
     Clinical and molecular features of subungual melanomas are site-specific and distinct from acral melanomas.
     Melanoma Res. 2020;30:562-573.
     PubMed     Abstract available
     
     
     
253. MIKKELSEN LH, Maag E, Andersen MK, Kruhoffer M, et al
     The molecular profile of mucosal melanoma.
     Melanoma Res. 2020;30:533-542.
     PubMed     Abstract available
     
     
     
254. 
     Paradox in melanoma: more patients fewer publications: Retraction.
     Melanoma Res. 2020;30:632.
     PubMed    
     
     
     
255. IPENBURG NA, van der Hage JA, Newton-Bishop JA, Harland M, et al
     Sentinel node biopsy in cutaneous melanoma patients with germline CDKN2A mutations.
     Melanoma Res. 2020;30:630-631.
     PubMed    
     
     
     
256. VELTER C, Sakkal M, Robert C
     Bariatric surgery in a patient treated with targeted therapies for metastatic melanoma: a case report.
     Melanoma Res. 2020;30:629-630.
     PubMed    
     
     
     
257. AYAZ T, Ramachandran V, Loya A, Patel S, et al
     Impact of marital status on survival in cutaneous melanoma.
     Melanoma Res. 2020;30:628-629.
     PubMed    
     
     
     
258. MARCAILLOU M, Linder C, Chaltiel L, Sibaud V, et al
     PD-1 inhibitors might limit the development of brain metastases in patients with advanced melanoma.
     Melanoma Res. 2020;30:580-589.
     PubMed     Abstract available
     
     
     November 2020
259. MURRIA ESTAL R, de Unamuno Bustos B, Perez Simo G, Simarro Farinos J, et al
     MicroRNAs expression associated with aggressive clinicopathological features and poor prognosis in primary cutaneous melanomas.
     Melanoma Res. 2020 Nov 23. doi: 10.1097/CMR.0000000000000709.
     PubMed     Abstract available
     
     
     
260. NUNEZ ABAD M, Saval Victoria A, Franco La Rosa M, Berrocal A, et al
     Infusion reaction to nivolumab in a metastatic melanoma patient. Safe switch to another anti-programmed death-1: a case report.
     Melanoma Res. 2020 Nov 23. doi: 10.1097/CMR.0000000000000710.
     PubMed     Abstract available
     
     
     
261. HODI FS, Chapman PB, Sznol M, Lao CD, et al
     Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218).
     Melanoma Res. 2020 Nov 23. doi: 10.1097/CMR.0000000000000708.
     PubMed     Abstract available
     
     
     
262. DUDDA M, Mann C, Heinz J, Schmidgen I, et al
     Hemophagocytic lymphohistiocytosis of a melanoma patient under BRAF/MEK-inhibitor therapy following anti-PD1 inhibitor treatment: a case report and review to the literature.
     Melanoma Res. 2020 Nov 23. doi: 10.1097/CMR.0000000000000703.
     PubMed     Abstract available
     
     
     
263. LIU WK, Naban N, Kaul A, Patel N, et al
     Life-threatening polymyositis with spontaneous hematoma induced by nivolumab in a patient with previously resected melanoma.
     Melanoma Res. 2020 Nov 13. doi: 10.1097/CMR.0000000000000706.
     PubMed     Abstract available
     
     
     
264. BAO R, Surriga O, Olson DJ, Allred JB, et al
     Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic target.
     Melanoma Res. 2020 Nov 6. doi: 10.1097/CMR.0000000000000701.
     PubMed     Abstract available
     
     
     
265. ANDERSON TS, Wooster AL, La-Beck NM, Saha D, et al
     Antibody-drug conjugates: an evolving approach for melanoma treatment.
     Melanoma Res. 2020 Nov 6. doi: 10.1097/CMR.0000000000000702.
     PubMed     Abstract available
     
     
     
266. CYBULSKA-STOPA B, Zietek M, Kaminska-Winciorek G, Czarnecka AM, et al
     Anti-programmed cell death-1 therapy in octogenarian and nonagenarian advanced/metastatic melanoma patients.
     Melanoma Res. 2020 Nov 6. doi: 10.1097/CMR.0000000000000705.
     PubMed     Abstract available
     
     
     
267. BENIEY M, Tran A, Boulva K
     Mapping sentinel lymph nodes in cutaneous melanoma: a vast array of perioperative imaging modalities.
     Melanoma Res. 2020 Nov 5. doi: 10.1097/CMR.0000000000000704.
     PubMed     Abstract available
     
     
     October 2020
268. FARRICHA V, Quaglino P, Brizio M, de Terlizzi F, et al
     Safety and efficacy of electrochemotherapy in a series of patients with nonmetastasized primary or recurrent anorectal malignant melanoma.
     Melanoma Res. 2020 Oct 8. doi: 10.1097/CMR.0000000000000699.
     PubMed     Abstract available
     
     
     September 2020
269. LEE S, Suh HB, Choi SJ, Kang J, et al
     Identification of prognostic mRNAs in metastatic cutaneous melanoma.
     Melanoma Res. 2020 Sep 29. doi: 10.1097/CMR.0000000000000697.
     PubMed     Abstract available
     
     
     
270. MATTEI J, Ballhausen A, Bassett R, Shephard M, et al
     A phase II study of the insulin-like growth factor type I receptor inhibitor IMC-A12 in patients with metastatic uveal melanoma.
     Melanoma Res. 2020 Sep 21. doi: 10.1097/CMR.0000000000000694.
     PubMed     Abstract available
     
     
     
271. CHANG LW, Badal B, Lu CJ, Solovyov A, et al
     An integrative approach identifies dysregulated long non-coding RNAs as microRNA decoys during nevus to melanoma transformation.
     Melanoma Res. 2020 Sep 21. doi: 10.1097/CMR.0000000000000695.
     PubMed     Abstract available
     
     
     
272. BYRON Y, Nott L, Shackleton M
     Case report: acute tumour lysis syndrome following encorafenib and binimetinib for v600E metastatic melanoma with large intra-abdominal mass.
     Melanoma Res. 2020 Sep 21. doi: 10.1097/CMR.0000000000000696.
     PubMed    
     
     
     April 2020
273. ROS-MONTANA J, Saoudi-Gonzalez N, Ortiz-Velez C, Munoz-Couselo E, et al
     The role of ipilimumab after anti-PD-1 treatment: two case reports and a literature review.
     Melanoma Res. 2020;30:209-212.
     PubMed     Abstract available
     
     
     
274. TRUONG A, Hyngstrom JR, Andtbacka RHI, Noyes RD, et al
     Recurrence risk of early-stage melanoma of the external ear: an investigation of surgical approach and sentinel lymph node status.
     Melanoma Res. 2020;30:173-178.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.